Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Atripla | Efavirenz, emtricitabine, tenofovir disoproxil fumarate | HIV | List with clinical criteria and/or conditions | Complete | ||
| Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| Campral | Acamprosate calcium | Alcohol Abstinence | List with clinical criteria and/or conditions | Complete | ||
| Emend | Aprepitant | Nausea and Vomiting, Chemotherapy induced | List with clinical criteria and/or conditions | Complete | ||
| Xyrem | Sodium oxybate | Narcolepsy | Withdrawn | |||
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) | Do not list | Complete | ||
| Elaprase | Idursulfase | Mucopolysarccharidosis II (MPS II), Hunter Syndrome | Do not list | Complete | ||
| Humira | Adalimumab | Crohn's disease | List with clinical criteria and/or conditions | Complete | ||
| Lucentis | Ranibizumab | Macular degeneration, age-related | List with clinical criteria and/or conditions | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | List with clinical criteria and/or conditions | Complete |
Last Updated : May 14, 2024